The effect of quercetin on iron overload and inflammation in ß-thalassemia major patients: A double-blind randomized clinical trial.

ABSTRACT

OBJECTIVES: The aim of this study was to determine whether quercetin can reduce iron overload and inflammation in thalassemic patients. METHODS: Eighty four patients were recruited to this study and randomly assigned to two groups 42 patients received a 500 mg/day quercetin tablet and 42 others took a 500 mg/day starch placebo for 12 weeks. Demographic, anthropometric and biochemical evaluation were performed. RESULTS: ANCOVA analysis revealed that compared to the control group, quercetin could reduce high sensitivity C-reactive protein (hs-CRP) (P = 0.046), iron (p = 0.036), ferritin (p = 0.043), and transferrin saturation (TS) (p = 0.008) and increase transferrin (p = 0.045) significantly, but it had no significant effect on total iron binding capacity (TIBC) (p = 0.734) and tumor necrosis factor α (TNF-α) (p = 0.310). CONCLUSIONS: Quercetin could ameliorate the iron status in thalassemia major, but its effect on inflammation is indistinctive.